Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
Conditions
Interventions
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Placebo
Locations
26
United States
Praxis Research Site
Phoenix, Arizona, United States
Praxis Research Site
DeLand, Florida, United States
Praxis Research Site
Miami Lakes, Florida, United States
Praxis Research Site
Chicago, Illinois, United States
Praxis Research Site
Lafayette, Louisiana, United States
Praxis Research Site
Bethesda, Maryland, United States
Start Date
December 11, 2024
Primary Completion Date
November 24, 2025
Completion Date
December 8, 2025
Last Updated
May 31, 2025
NCT07219407
NCT05605756
NCT02365610
NCT02369471
NCT03283371
Lead Sponsor
Praxis Precision Medicines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions